Tacrolimus, a calcineurin inhibitor, is beneficial in the treatment of some MG patients by affecting muscle contraction (regulating intracellular calcium release channels and ryanodine receptors that increase muscle strength), glucocorticoid receptors (increasing intracellular concentrations of steroids and blocking steroid export mechanisms), and increasing T-cell apoptosis (Ponseti et al. 2008), with long-term use significantly reducing the need for oral steroids in MG patients (Alhaidar et al. 2022). Here, NR3C1 is linked to myasthenia gravis.